Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. Oktober 2017 12:45 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic Mice

CAMBRIDGE, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study in transgenic mice...
03. Oktober 2017 08:00 ET | Quelle: Editas Medicine

Editas Medicine to Participate in Investor Conferences in October

CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
26. September 2017 16:01 ET | Quelle: Editas Medicine

Editas Medicine Receives EMA’s Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10

CAMBRIDGE, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the European Medicines Agency (EMA) granted Orphan...
12. September 2017 08:00 ET | Quelle: Editas Medicine

Editas Medicine Initiates Clinical Natural History Study to Evaluate Patients with Leber Congenital Amaurosis Type 10 (LCA10)

CAMBRIDGE, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that the Company initiated a clinical natural history...
05. September 2017 08:00 ET | Quelle: Editas Medicine

Editas Medicine to Participate in Morgan Stanley 15th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in a fireside chat at the...
09. August 2017 16:03 ET | Quelle: Editas Medicine

Editas Medicine Announces Second Quarter 2017 Results and Update

Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT-101 made significant progress toward clinical trials Achieved research milestone in Juno Therapeutics, Inc., collaboration ...
09. August 2017 16:01 ET | Quelle: Editas Medicine

Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment

CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it achieved a second milestone under its collaboration...
07. August 2017 08:00 ET | Quelle: Editas Medicine

Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results

CAMBRIDGE, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
13. Juni 2017 08:00 ET | Quelle: Editas Medicine

Editas Medicine to Participate in Investor Conferences in June

CAMBRIDGE, Mass., June 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
31. Mai 2017 16:01 ET | Quelle: Editas Medicine

Editas Medicine Names Andrew Hirsch to Board of Directors

CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Andrew Hirsch to its board of directors,...

Vorherige Seite